Hirsutism, Hair Loss, and Hormonal Hair Disorders: Causes, Diagnosis, and Treatments

What this article establishes and what it does not

Hirsutism, the growth of coarse, pigmented terminal hair on a woman's face, chest, abdomen, back, or inner thighs, is distinct from hypertrichosis, which is generalized excess hair growth unrelated to androgens. It is diagnosed clinically with the modified Ferriman-Gallwey (mFG) score, and a score of 8 or higher confirms hirsutism in most population groups (some clinicians use a lower threshold, around 6, for women of East Asian ancestry). Polycystic ovary syndrome (PCOS) is the underlying cause in the large majority of hirsutism cases seen in reproductive-age women, and the same androgen excess that drives facial and body hair growth can also miniaturize scalp follicles, so hirsutism and female pattern hair loss often occur in the same patient. Hirsutism that develops rapidly over weeks to months, or that comes with voice deepening or clitoral enlargement, is not typical of PCOS and warrants evaluation for an androgen-secreting tumor rather than routine hormonal therapy.

This page distinguishes FDA-approved indications from widely used off-label prescribing and from cosmetic procedures, because the strength of evidence differs materially between those categories. Several precise statistics that circulated in earlier versions of hair-loss content online (exact trial percentages, confidence intervals, and effect sizes attributed to specific studies) could not be verified against a checked primary source for this draft and have been described in general terms instead. Anyone using a specific number in a clinical conversation should confirm it against the original trial or guideline first.

Hirsutism versus hypertrichosis, and how it is worked up

Hirsutism is androgen-dependent; hypertrichosis is not. The distinction matters because hirsutism prompts a hormonal workup and hypertrichosis generally does not.

A standard laboratory workup for new hirsutism typically includes total and free testosterone, DHEA-S, and sex hormone-binding globulin (SHBG). A markedly elevated total testosterone or a rapid, severe presentation raises concern for an androgen-secreting tumor and should prompt imaging and specialist referral. A recent case report literature discusses postmenopausal women with androgen-secreting ovarian pathology in whom imaging was unrevealing and diagnostic surgery was still pursued because clinical and biochemical evidence of virilization was strong; this illustrates that a clean scan does not rule out a hormone-secreting source when the clinical picture is concerning (case report discussion, 2025). This is a narrow, case-level observation, not a general recommendation to pursue surgery without imaging findings, and it applies to atypical or postmenopausal presentations rather than typical adolescent-onset PCOS-related hirsutism.

Separately, biochemical hyperandrogenemia and clinical hirsutism do not always track together in women being evaluated for menstrual irregularity, which is part of why PCOS diagnosis relies on a combination of clinical, biochemical, and ultrasound criteria rather than any single test (hyperandrogenemia and menstrual irregularity, 2025). Congenital adrenal hyperplasia (non-classical form), thyroid dysfunction, hyperprolactinemia, and, rarely, Cushing syndrome round out the differential.

Why the same hormone drives hair growth in one place and hair loss in another

Dihydrotestosterone (DHT), produced from testosterone by 5-alpha reductase, binds androgen receptors in hair follicles. In genetically sensitive scalp follicles, DHT shortens the growth (anagen) phase and progressively miniaturizes the follicle over repeated cycles. In facial and body follicles, the same hormone does the opposite: it converts fine vellus hair into coarse terminal hair. Genetic variation in the androgen receptor gene, carried on the X chromosome, is a major contributor to individual susceptibility to male pattern hair loss, and genome-wide association work has linked variants near this gene to pattern baldness risk, though the exact number of contributing loci and their effect sizes are an active research area rather than a settled figure worth quoting precisely.

A decision framework: matching the presentation to the likely cause and the reasonable next step

The categories below are not mutually exclusive and the "next step" column describes a reasonable starting conversation with a clinician, not a diagnosis.

Male pattern hair loss: what is FDA-approved and what is off-label

Male pattern hair loss (androgenetic alopecia) is commonly staged with the Hamilton-Norwood classification, from minimal recession to complete crown and vertex loss. It becomes common with age, though exact age-specific prevalence figures vary across the population studies that report them and should be checked against a current source rather than quoted as a fixed number.

Two treatments carry FDA approval specifically for male pattern hair loss:

• Finasteride 1 mg daily (Propecia) inhibits 5-alpha reductase type II and lowers scalp DHT. Randomized trial evidence supports increased hair count relative to placebo over roughly a year of treatment. Sexual side effects (reduced libido, erectile difficulty) occur in a minority of users and should be discussed before starting.
• Minoxidil topical solution or foam (2% or 5%) is applied directly to the scalp; its mechanism likely involves prolonging the anagen phase, though the full mechanism is not completely defined.

Two additional options are used off-label with a different evidence base:

• Low-dose oral minoxidil (roughly 0.625 to 2.5 mg daily) is increasingly prescribed off-label. Comparative data suggest efficacy similar to topical 5% minoxidil with better adherence in some patients, alongside a recognized risk of unwanted hair growth at other body sites (hypertrichosis), which is usually mild and reverses on stopping the drug. This is off-label use and dosing should be individualized by a prescriber, not chosen from a general article.
• Dutasteride inhibits both 5-alpha reductase type I and II and is FDA-approved for benign prostatic hyperplasia, not for hair loss. It is used off-label for male pattern hair loss, and some head-to-head trial data suggest a larger effect on hair count than finasteride, though dutasteride also carries a longer half-life and less long-term safety data specific to the hair-loss indication.

Female pattern hair loss: recognition and treatment options

Female pattern hair loss presents as diffuse thinning over the crown and frontal scalp with the frontal hairline generally preserved, and is often classified with the Ludwig scale. A substantial share of women with FPHL have normal circulating androgen levels, meaning the disorder often reflects follicular sensitivity rather than measurable androgen excess, which is one reason FPHL and hirsutism do not always occur together even though they share biology.

Minoxidil (2% solution twice daily, or 5% foam once daily) is the only topical treatment carrying FDA approval specifically for FPHL, and professional dermatology guidance treats it as first-line pharmacologic therapy.

Spironolactone (commonly 100 to 200 mg daily) is used off-label for FPHL, particularly when androgen levels are elevated. It is an androgen receptor blocker with a long track record in dermatology, though the randomized trial base specific to FPHL is smaller than for hirsutism. Women of childbearing potential need reliable contraception on spironolactone because of a teratogenic risk (feminization of a male fetus).

Finasteride is not FDA-approved for women and is contraindicated in pregnancy; it is occasionally used off-label in postmenopausal women, but the supporting evidence is thinner than the male pattern hair loss data and doses used vary by prescriber.

Platelet-rich plasma (PRP) injections have shown improved hair density in some randomized trials, but PRP is a procedure rather than an FDA-cleared drug for FPHL, and protocols (number of sessions, spacing, preparation method) vary between clinics without a single standardized regimen.

Telogen effluvium: temporary shedding after a systemic trigger

Telogen effluvium (TE) is diffuse hair shedding that follows a physiological or psychological stressor pushing a larger-than-normal share of follicles into the resting (telogen) phase at once. Shedding typically begins roughly two to four months after the trigger, since telogen hairs are shed only when new anagen growth pushes them out.

Common triggers include major surgery, childbirth, rapid or sustained weight loss, severe infection, thyroid dysfunction, iron deficiency, and significant psychological stress. Reports following COVID-19 illness described a meaningful minority of survivors noticing hair shedding in the weeks after acute illness, consistent with TE as a post-infectious phenomenon, though exact rates vary by cohort and should not be quoted as a fixed percentage.

The hair pull test and trichoscopy help distinguish TE from androgenetic alopecia; TE typically shows an increased proportion of club-root telogen hairs without the follicular miniaturization seen in pattern hair loss. Management centers on correcting the underlying trigger. Many hair specialists target a ferritin level meaningfully above the lab's lower limit of normal (a commonly cited target is above roughly 70 ng/mL) when treating TE associated with iron deficiency, although randomized trial evidence specifically testing iron repletion targets in non-anemic TE patients is limited. Thyroid correction is appropriate when TSH is abnormal. Topical minoxidil can shorten recovery by recruiting follicles back into anagen, but it does not treat the underlying cause. Most straightforward cases resolve within 6 to 12 months once the trigger is removed. Chronic telogen effluvium, persisting beyond 6 months and often without an identifiable trigger, tends to fluctuate rather than progress to permanent loss, and management leans toward reassurance and correcting any nutritional deficiency found.

Alopecia areata: an autoimmune process, not a hormonal one

Alopecia areata is an autoimmune condition in which T-cell-mediated inflammation attacks the hair follicle bulb, producing focal, non-scarring hair loss, typically as round or oval patches. It can affect eyebrows, eyelashes, or body hair, and severe forms include alopecia totalis (complete scalp loss) and alopecia universalis (total body hair loss). Geometric nail pitting is a recognized associated finding in a meaningful minority of patients. Trichoscopy shows exclamation-mark hairs and yellow or black dots at the edge of active patches.

For limited disease affecting less than half the scalp, intralesional corticosteroid injections are standard care, and topical high-potency corticosteroids are an alternative for patients who prefer to avoid injections, generally with a lower response rate.

For severe alopecia areata (roughly 50% or more of the scalp affected), two oral JAK inhibitors carry FDA approval as of their approval dates: baricitinib (Olumiant), approved in June 2022 for adults with severe alopecia areata, and ritlecitinib (Litfulo), approved in June 2023 for patients age 12 and older. Both were approved on the strength of placebo-controlled phase 3 trials in which a meaningfully larger share of treated patients reached substantial scalp regrowth than patients on placebo. The exact response rates reported in those trials are specific numbers that should be verified against the published trial reports before being quoted to a patient, since this draft could not independently confirm the precise figures that circulated in earlier hair-loss content. Both drugs carry the class warnings associated with JAK inhibitors (infection risk, thrombosis, and others reflected in their FDA labeling), and eligibility should be discussed with a dermatologist familiar with the current label.

Treating hirsutism: hormonal therapy, an antiandrogen, and cosmetic options

Combined oral contraceptives containing a low-androgenic progestin are typically first-line pharmacologic treatment for women with hirsutism who are not seeking pregnancy. They suppress LH-driven ovarian androgen production and raise SHBG, which lowers free testosterone.

Spironolactone (commonly 100 to 200 mg daily) is added when oral contraceptive therapy alone is insufficient after several months. It blocks the androgen receptor and weakly inhibits 5-alpha reductase. Randomized trial evidence, summarized in prior systematic reviews, supports a meaningful reduction in hirsutism scores compared with placebo, though the underlying trials are generally small and of variable quality, which is worth knowing before treating a specific effect-size figure as precise. Potassium should be monitored, especially in patients with kidney disease or those taking an ACE inhibitor or ARB; monthly checks for the first few months is a common practice pattern.

For women with PCOS whose hirsutism and metabolic picture both need attention, metformin is sometimes used as an adjunct, primarily for its metabolic effects rather than as a direct antiandrogen; a recent review outlines both the potential benefits and the practical limitations of metformin in PCOS management, including modest and inconsistent effects on hirsutism itself compared with its effects on cycle regularity and insulin resistance (metformin in PCOS, 2025).

Eflornithine hydrochloride 13.9% cream (Vaniqa) is FDA-approved specifically for reducing unwanted facial hair growth in women. It inhibits an enzyme involved in hair follicle growth and slows hair growth rather than removing existing hair; it is generally used alongside a hair-removal method such as laser rather than as a standalone therapy.

Laser hair removal (commonly Nd:YAG or alexandrite wavelengths depending on skin tone) is the most durable cosmetic option, usually requiring multiple sessions because only follicles in the growth phase respond at any given treatment. It does not treat the underlying hormonal cause, so pharmacologic treatment is often run in parallel when an androgen excess condition is identified.

Response to treatment is typically reassessed with the mFG score at roughly six-month intervals, since hair growth cycles are slow and earlier assessment may understate benefit.

Nutrition and lifestyle factors across these conditions

Nutritional status can worsen any of these hair conditions and is sometimes the primary driver of shedding rather than a minor contributor. Iron deficiency is the most studied nutritional factor in telogen effluvium; observational studies have linked low ferritin to chronic diffuse shedding, though the field lacks a single universally agreed ferritin threshold, and the commonly cited targets above should be treated as clinical practice patterns rather than settled trial-proven cutoffs. Zinc deficiency has been associated with alopecia areata in observational data, though this does not establish that zinc supplementation treats the condition.

Biotin deficiency is genuinely rare outside of hereditary biotinidase deficiency or prolonged raw egg white consumption, yet biotin supplementation is widely self-prescribed for hair concerns. The FDA issued a safety communication in 2019 warning that high-dose biotin can interfere with biotin-based immunoassays, producing falsely low troponin results or inaccurate thyroid hormone values; anyone taking high-dose biotin should tell their clinician before cardiac or thyroid bloodwork.

Rapid weight loss, including weight loss driven by GLP-1 receptor agonists such as semaglutide or tirzepatide, can trigger telogen effluvium in a minority of users through the caloric-restriction and rapid-weight-change mechanism rather than a direct drug effect. Adequate protein intake and periodic ferritin monitoring during active, rapid weight loss are reasonable precautions, though there is no dedicated large trial establishing exact intake targets for preventing this specific shedding pattern.

What is established, what is plausible, and what is not established

Established: hirsutism is diagnosed with the mFG score, PCOS is the dominant cause in reproductive-age women, DHT drives both scalp miniaturization and facial/body terminal hair growth, and finasteride, minoxidil, eflornithine, baricitinib, and ritlecitinib each carry a specific FDA-approved indication described above.

Plausible but not fully settled: precise trial-derived effect sizes (exact percentages, hazard ratios, or point estimates) that were widely circulated in earlier hair-loss content for several of these drugs could not be verified against a confirmed primary source in this draft and should be checked against the original trial publication before being used in patient counseling or marketing claims. The ideal ferritin target for treating telogen effluvium, the role of dutasteride relative to finasteride long-term, and off-label finasteride dosing in postmenopausal women all fall into this category.

Not established from the material available here: that any over-the-counter supplement (including biotin, at ordinary doses) treats androgenetic alopecia, hirsutism, or alopecia areata in the absence of a diagnosed deficiency.